This page catalogs companies developing exosome-based or extracellular vesicle (EV) therapeutics for Alzheimer's disease. Exosomes are small vesicles (30-150nm) that naturally cross the blood-brain barrier and can be engineered to deliver therapeutic cargo — including siRNA, ASOs, small molecules, and proteins — to target brain cells[kalluri2020][sun2025].
| Attribute | Value |
|---|---|
| Founded | 2005 |
| Headquarters | San Diego, CA |
| Ticker | NASDAQ: CAPR |
| Platform | MSC-derived exosomes (CAP-2003) |
Capricor develops cell-derived extracellular vesicle therapeutics. Its lead candidate CAP-2003 (CK+EVs) is in development for inflammatory and neurological conditions. The company leverages proprietary isolation technology to produce clinical-grade EVs.
| Attribute | Value |
|---|---|
| Founded | 2005 |
| Headquarters | Boston, MA |
| Ticker | NASDAQ: PRTC |
| Platform | Glymphatic delivery, LyoPho™ formulation |
PureTech Health develops platform technologies for CNS drug delivery. Its internal pipeline includes LYT-100 (deupirfenone) for AD-related neuroinflammation. The company has established R&D capabilities in EV-based delivery systems.
| Attribute | Value |
|---|---|
| Founded | 2016 |
| Headquarters | Oxford, UK |
| Ticker | Private |
| Platform | Exosome engineering (DeliverEX™) |
Evox Therapeutics develops exosome-based therapeutics using its DeliverEX™ platform. The company focuses on CNS delivery of RNA therapeutics and has partnerships with major pharma.
| Attribute | Value |
|---|---|
| Founded | 2015 |
| Headquarters | Cambridge, MA |
| Ticker | NASDAQ: CDAK (delisted 2024) |
| Platform | engEx™ exosome platform |
Codiak was a pioneer in exosome therapeutics with its engEx™ platform. The company developed exosome engineered with targeting moieties and loaded with therapeutic cargo. While the company underwent restructuring, its platform technology remains influential.
| Company | Focus | Status |
|---|---|---|
| NeuroDex | EV biomarkers for AD | Clinical |
| Exosome Diagnostics (Bio-Techne) | EV-based diagnostics | Commercial |
| amsbio | Exosome isolation reagents | Commercial |
| Systemic蜗牛 | EV therapeutics | Preclinical |
| BreHealth | EV drug delivery platform | Research |
Currently limited specific EV trials for AD, but multiple trials using MSC-derived products have indirect relevance to EV therapeutics.
| Factor | Traditional mAb | EV-Based |
|---|---|---|
| BBB crossing | Limited | Natural capability |
| Target specificity | High | Tunable |
| Manufacturing scale | Mature | Developing |
| Cargo flexibility | Proteins only | siRNA, ASO, small molecules |